As of 2025-07-12, the Relative Valuation of Innate Pharma SA (IPH.PA) is (2.01) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.50 EUR, the upside of Innate Pharma SA based on Relative Valuation is -234.0%.
The range of the Relative Valuation is (1.93) - (3.31) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 2.4x - 6.2x | 3.0x |
| Forward P/E multiples | 3.6x - 6.8x | 4.5x |
| Fair Price | (1.93) - (3.31) | (2.01) |
| Upside | -228.6% - -320.1% | -234.0% |
| Date | P/E |
| 2025-07-11 | -2.80 |
| 2025-07-10 | -2.82 |
| 2025-07-09 | -2.85 |
| 2025-07-08 | -2.81 |
| 2025-07-07 | -2.85 |
| 2025-07-04 | -2.84 |
| 2025-07-03 | -2.84 |
| 2025-07-02 | -2.83 |
| 2025-07-01 | -2.85 |
| 2025-06-30 | -2.84 |
| 2025-06-27 | -2.91 |
| 2025-06-26 | -2.88 |
| 2025-06-25 | -2.82 |
| 2025-06-24 | -2.80 |
| 2025-06-23 | -2.85 |
| 2025-06-20 | -2.96 |
| 2025-06-19 | -3.07 |
| 2025-06-18 | -3.10 |
| 2025-06-17 | -3.07 |
| 2025-06-16 | -3.09 |
| 2025-06-13 | -3.15 |
| 2025-06-12 | -3.19 |
| 2025-06-11 | -3.26 |
| 2025-06-10 | -3.33 |
| 2025-06-09 | -3.52 |
| 2025-06-06 | -3.57 |
| 2025-06-05 | -3.57 |
| 2025-06-04 | -3.60 |
| 2025-06-03 | -3.62 |
| 2025-06-02 | -3.61 |
| 2025-05-30 | -3.68 |
| 2025-05-29 | -3.69 |
| 2025-05-28 | -3.65 |
| 2025-05-27 | -3.58 |
| 2025-05-26 | -3.66 |
| 2025-05-23 | -3.66 |
| 2025-05-22 | -3.67 |
| 2025-05-21 | -3.64 |
| 2025-05-20 | -3.65 |
| 2025-05-19 | -3.61 |
| 2025-05-16 | -3.57 |
| 2025-05-15 | -3.58 |
| 2025-05-14 | -3.64 |
| 2025-05-13 | -3.71 |
| 2025-05-12 | -3.75 |
| 2025-05-09 | -3.81 |
| 2025-05-08 | -3.87 |
| 2025-05-07 | -3.76 |
| 2025-05-06 | -3.59 |
| 2025-05-05 | -3.56 |